Short answer
Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Natalie Holles becomes CEO, President, and Class I director effective April 30, 2026, replacing founder Elisabet de los Pinos.
Aura Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Natalie Holles becomes CEO, President, and Class I director effective April 30, 2026, replacing founder Elisabet de los Pinos
- Leadership transition brings rare-disease commercialization experience after Holles’ CEO roles at Third Harmonic Bio and Audentes Therapeutics
- New CEO compensation includes $700,000 salary, 55% target bonus, and equity awards totaling approximately 3.0% of outstanding shares
- De los Pinos receives 12 months’ salary continuation, potential 18 months’ COBRA support, and accelerated equity vesting during consulting through October 30, 2026
- Founder departure was explicitly reported as unrelated to any dispute, reducing immediate governance concern despite substantial transition benefits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, signaling supplemental investor disclosure
- Exhibit excluded from Section 18 liability and not incorporated by reference into other filings
- Investor-relevant information resides in Exhibit 99.1, not the brief Item 7.01 text
Item 8.01 · Other Events
- Forward-looking statement disclaimer covering clinical development, regulatory approval, financing, and trial execution risks
- Phase 3 Special Protocol Agreement with FDA does not eliminate regulatory or trial-outcome uncertainty
- Investor focus: enrollment, clinical data timing, cash sufficiency, and potential divergence between interim and final results
Item EX-99.1 · Exhibit EX-99.1
- Natalie Holles appointed CEO, President, and director effective April 30, 2026, replacing founder Elisabet de los Pinos
- Phase 3 CoMpass enrollment reached 86 patients, with more than 25 additional patients scheduled or identified for screening
- Management reiterates enrollment completion by mid-2026 and topline data in the second half of 2027
- CEO transition shifts leadership toward late-stage execution and potential commercialization of bel-sar
- FDA Special Protocol Assessment, Orphan Drug, and Fast Track designations support regulatory positioning but do not assure approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aura Biosciences, Inc. 8-K filings
Get the next AURA 8-K as it lands
Follow AURA for push alerts, or ask the research agent what this filing means.